ISPO

Cancer Detection and Prevention Volume 23 / Issue 4 (Jul-Aug 1999)

Table of Contents and Editor's Notes

The peer review process occasionally results in approval of controversial publications that do not necessarily reflect the viewpoint of the editors. Readers of the journal are encouraged to critically review and comment on presented data by submitting a "Letter to the Editor" that may be reprinted in a subsequent issue.

Genetic and Epigenetic Changes of Intercellular Communication Genes During Multistage Carcinogenesis - A Review

Hiroshi Yamasaki, M.D, Yasufumi Omori, M.D., Maria-Lucia Zaidan-Dagli, M.D., Nikolai Mironov, M.D., Marc Mesnil, M.D., and Vladimir Krutovskikh, M.D.

A decrease in Gap-Junctional intercellular communication in certain tumors often occurs as a result of epigenetic inactivation of connexin (gap junction protein) genes. Normal cell growth control may be recovered by transfection of connexin genes into tumor and surrounding cells. >>>

The in vitro Effect of the Tumor Promoter 12-O-Tetradecanoylphorbol-13-Acetate on Sertoli Cell Morphology

Mirsini Kouloukoussa, Ph.D., Evridiki Panagopoulou, B.S., and Evangelos Marinos, Ph.D.

Immature Sertoli cells in vitro when treated with the tumor promoter TPA (12-0-tetradecanoylphorbol-13-acetate) had decreased astrocytic cytoplasmic extensions and reduced cellular size. >>>

Percutaneous Progesterone Use and Risk of Breast Cancer: Results From a French Cohort Study of Premenopausal Women with Benign Breast Disease

G. Plu-Bureau, M.D., Ph.D., M. G. Lê, M.D., J. C. Thalabard, M.D., Ph.D., R. Sitruk-Ware, M.D., and P. Mauvais-Jarvis, M.D.

Administration of percutaneous progesterone alone did not alter breast cancer risk in a cohort of 1150 premenopausal women with benign breast disease. However, the combined use of percutaneous progesterone and oral progestogens significantly lowered the risk of breast cancer. >>>

nm-23, c-Erbb-2, and Progesterone Receptor Expression in Invasive Breast Cancer: Correlation with Clinicopathologic Parameters

Lydia L. Nakopoulou, M.D., Dimitris Tsitsimelis, M.D., Andreas Ch. Lazaris, M.D., Anastasia Tzonou, M.D., Hara Gakiopoulou, M.D., Christina Ch. Dicoglou, M.D., and Panayiotis S. Davaris, M.D.

Absence of the antimetastasis nm23 H1 gene product NDP (nucleotide diphosphate) kinase A immunoexpression and the synchronous overexpression of C-erb-B2 protein was associated with extensive nodal metastases. A significant qualitative and quantitative correlation existed between nm23 positivity and progesterone receptor positivity. >>>

Prostate Cancer Screening: Promise and Peril - A Review

Paul A. Godley, M.D., Ph.D.

The current state and recommendations for prostate cancer screening are summarized in this review evaluating digital rectal examination, prostate-specific antigen and transrectal ultrasonography. Prostate cancer incidence may be reduced by chemoprevention using finasterid and by nutritional prevention with alpha-tocopherol and beta-carotene and by selenium supplementation. >>>

Neuron-Specific Enolase, Thymidine Kinase, and Tissue Polypeptide-Specific Antigen in Diagnosis and Response to Chemotherapy of Small-Cell Lung Cancer

Vincenzo Abbasciano, M.D., Sergio Sartori, M.D., Lucio Trevisani M.D. Ingrid Nielsen, M.D. Eros Ferrazzi, M.D., Antonio Bononi, M.D. Silvia Toso, M.D., Giorgio Crepaldi, M.D., Maria Pia Bianchi, Giuseppe Gilli Giorgio Zavagli M.D.

In patients with small-cell lung cancer levels of neuron-specific enolase (NSE) and polypeptide-specific antigen (TPS) were significantly higher than those of thymidine kinase (TK). Chemotherapy with no response or partial response was associated with NSE and TPS abnormal values more often than with TK. The three markers did not distinguish limited disease from extensive disease. >>>

A Receptor Tyrosine Kinase, UFO/Axi, and Other Genes Isolated by a Modified Differential Display PCR are Overexpressed in Metastatic Prostatic Carcinoma Cell Line DU145

A. N. K Jacob, Ph.D., John Kalapurakal, M.D., William R. Davidson, B.S., Geeta Kandpal M.S., Naomi Dunson, Yatindra Prashar, Ph.D., and Rajendra P. Kandpal, Ph.D.

The receptor tyrosine kinase UFO/Axl was higher in the metastatic prostate carcinoma cell line DU145 than in normal cells and in the prostatic carcinoma cell line PC-3. The receptor UFO/Axl may also cause prostate tumorigenesis and metastasis. >>>

Prospects of Immunotherapy for the Treatment of Prostate Carcinoma - A Review

Gilda G. Hillman, Ph.D., Jeffrey A. Triest, M.D., Michael L. Cher, M.D., Sosa V. Kocheril, M.D., and Bharat R. Talati, M.Sc.

This review summarizes the potential immunotherapeutic approaches to metastatic prostate carcinoma. In tumor models prostate carcinoma may respond to treatment with interleukin-2, interferon gamma, tumor necrosis factor-alpha and granulocyte macrophage colony-stimulating factor. Other potential therapies include combinations of cytokines, cytokine gene therapy, immunization to tumor antigens and adoptive transfer of dendritic cells sensitized to prostate cancer antigens. >>>

Daunorubicin-Induced Pathology in the Developing Hamster Molar Tooth Germ in Vitro

D. M. Lyaruu, Ph.D., M. A. van Duin, B.Sc., T. J. M. Bervoets, B.Sc., A. L. J. J. Bronckers, Ph.D., and J. H. M. Wöltgens, Ph.D., D.D.S.

Daunarubicin was toxic to regions in proliferative stages of tooth development. The preameloblasts were the most sensitive cells to the drug, followed by the predontoblasts and proliferating cells in the dental pulp. >>>

5-Aminolevulinic Acid-Mediated Photodynamic Therapy of Lntraepithelial Neoplasia and Human Papillomavirus of the Uterine Cervix - A New Experimental Approach

Franz Wierrani M.D., Andreas Kubin, Ph.D. Rudolf Jindra, Ph.D., Michael Henry, M.D., Kamran Gharehbaghi M.D., Wolfgang Grin, M.D., Josef Söltz-Szötz, M.D., Werner Grünberger, M.D., and Gerhart Alth, M.D.

In 20 nonpregnant women cervical intraepithelial neoplasia grades I and II with human papilloma virus (HPV) infection responded to photodynamic therapy after 1, 3, 6 and 9 months. A complete response to treatment was obtained in 10 of 12 patients with low-risk HPV infection and in 10 of 13 cases with high-risk HPV types. >>>

 

Herbert E. Nieburgs, MD
Worcester, MA
1999